Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Regular Insulin

Recombinant protein · developed by Xeris Pharmaceuticals

Phase 2 Most advanced trial (none active)
XERS Developer
1 Registered trials

What is Regular Insulin?

Regular insulin is a recombinant human insulin that acts as an agonist of the insulin receptor to regulate blood glucose levels. It is studied in type 1 diabetes mellitus and insulin-dependent diabetes.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Recombinant protein
Therapy area
Endocrine
Developer
Xeris Pharmaceuticals (XERS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04074317 Phase 2 Diabetes Mellitus, Type 1 Completed XERS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diabetes Mellitus, Type 1Insulin-dependent Diabetes Mellitus

More from Xeris Pharmaceuticals

G-Pen Phase 2 PRAM9 Phase 2

Follow XERS, the company behind Regular Insulin

See XERS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

XERS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.